The FDA on December 3, 2019 approved TECENTRIQ® in combination with Paclitaxel protein-bound and Carboplatin for the first-line treatment of adult patients with metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. TECENTRIQ® is a product of Genentech Inc.
Bottom Ad
Advertisement
Subscribe
